Amlodipine Does Not Prevent Renal Stones and May Potentially Increase Risk
Amlodipine, a calcium channel blocker, is not recommended for the prevention or treatment of renal stones and may actually increase susceptibility to stone formation. The established pharmacologic agents for preventing recurrent nephrolithiasis are thiazide diuretics, citrate, and allopurinol—not calcium channel blockers like amlodipine 1.
Evidence from Guidelines
The American College of Physicians 2014 guidelines on nephrolithiasis management explicitly recommend pharmacologic monotherapy with thiazide diuretics, citrate, or allopurinol to prevent recurrent kidney stones when increased fluid intake fails 1. Notably, calcium channel blockers are completely absent from these evidence-based recommendations, indicating they have no established role in stone prevention.
The European Association of Urology 2025 guidelines similarly make no mention of calcium channel blockers for urolithiasis management 2, further confirming these agents are not part of standard stone prevention protocols.
FDA-Approved Indications
The FDA labeling for amlodipine specifies its approved uses as hypertension and angina management 3. While amlodipine does affect renal hemodynamics by decreasing renal vascular resistance and increasing glomerular filtration rate in hypertensive patients 3, there is no FDA-approved indication for kidney stone prevention or treatment.
Concerning Research Evidence
Animal studies suggest amlodipine may actually worsen stone formation. A 2013 experimental study demonstrated that amlodipine administration in rats with ethylene glycol-induced urolithiasis significantly increased:
- Hyperoxaluria and hypercalciuria
- Urine calcium oxalate levels
- Intratubular crystal depositions 4
The authors concluded that "amlodipine may increase susceptibility to urolithiasis by raising hyperoxaluria and hypercalciuria" 4.
Epidemiological Data
A large 2017 retrospective cohort study of 542,581 older adults compared kidney stone risk across antihypertensive classes. Calcium channel blockers showed no protective effect against kidney stones (HR 1.02; 95% CI 0.92-1.13) compared to beta-blockers, while thiazide diuretics demonstrated significant protection (HR 0.76; 95% CI 0.68-0.84) 5. This real-world evidence confirms that calcium channel blockers, including amlodipine, do not reduce stone risk.
Clinical Implications
What Amlodipine Does:
- Effectively controls blood pressure
- Improves renal hemodynamics in hypertensive patients 3
- May provide renoprotection in chronic kidney disease through BP control 6, 7
What Amlodipine Does NOT Do:
- Prevent kidney stone formation
- Facilitate stone passage
- Reduce urinary calcium excretion (unlike thiazides)
- Alter urinary pH or citrate levels (unlike citrate therapy)
Important Caveats
Do not confuse renoprotection with stone prevention. While amlodipine may slow CKD progression through BP control 6, this is mechanistically distinct from preventing crystallization and stone formation. The pathophysiology of stone prevention requires specific interventions targeting urinary supersaturation—something amlodipine does not accomplish.
If a patient requires both hypertension management and stone prevention, the appropriate strategy is:
- First-line: Thiazide diuretics (which address both conditions) 1
- If thiazides contraindicated: Use amlodipine for BP control PLUS add citrate or allopurinol specifically for stone prevention 1
The experimental evidence suggesting potential harm 4 combined with the complete absence of clinical benefit 5 makes amlodipine an inappropriate choice for stone prevention.